Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Change in Account Payables (2024 - 2025)

Historic Change in Account Payables for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$1.8 million.

  • Xilio Therapeutics' Change in Account Payables fell 54214.29% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2024, which is 17396.99% up from last year.
  • Latest data reveals that Xilio Therapeutics reported Change in Account Payables of -$1.8 million as of Q3 2025, which was down 54214.29% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Change in Account Payables ranged from a high of $2.1 million in Q2 2025 and a low of -$1.8 million during Q3 2025